PharmTech News

Articles

Under the agreement, Roche will have access to Promedior's lead product candidate, PRM-15, a recombinant form of human pentraxin-2 that can possibly treat a range of systemic fibrotic diseases.

Roche Completes Acquisition of Promedior for up to $1 Billion

Agnes Shanley is senior editor of Pharmaceutical Technology.

New funding brings competitors, and a leading healthcare products distributor, into the standardization effort.


Novartis, Kite, and Cardinal Health Invest in Cell and Gene Therapy Infrastructure

Catalent builds on its investment in cell and gene therapy development and manufacturing with the acquisition of MaSTherCell Global.

Catalent to Acquire MaSTherCell Global for $315 Million

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Bio/pharma researchers mobilize to diagnose and treat patients in pandemic threat.

The Call for a Rapid Response

The new facility, to be operated under the newly formed CDMO, The Center for Breakthrough Medicines, will be located in King of Prussia, PA, and will increase manufacturing capacity for cell and gene therapies.

The Discovery Labs, Deerfield Management Create New CDMO and Invest $1.1 Billion in New Cell and Gene Therapy Facility

Tina Morris will be taking on the role of executive director for AAPS.

AAPS Announces New Executive Director

The facility will produce parenteral products and delivery devices and is set to create 460 new jobs.

Eli Lilly to Invest $470 Million into New Pharma Manufacturing Facility

The amount was the third highest year recorded and investment has increased more than 400% since 2012.

BIA and Informa Pharma Intelligence Announce UK Biotech Raised $1.7 billion in 2019

The agreement centers around the development of new stem-cell derived allogeneic T-cell therapies for the treatment of cancer.

Astellas, Adaptimmune Form Cell Therapy Pact Worth Up to $897.5 million

Through the agreement, Eli will expand its immunology pipeline with lebrikizumab, Dermira’s novel, investigational, monoclonal antibody designed to bind interleukin-13 with high affinity.

Top News